How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

While there have been many sober warnings about AI and recursive self-improvement, Arianna Huffington argues that it is a ...

In Chapter 1, we defined the starting point as the minimum information of the universe. In Chapter 2, we examined the process by which differences are generated from that minimum information and ...

Abstract: In this article, we study the recursive algorithms for a class of separable nonlinear models (SNLMs) in which the parameters can be partitioned into a linear part and a nonlinear part. Such ...

Abstract: In this paper, some new schemes are developed to improve the tracking performance for fast and rapidly time-varying systems. A generalized recursive least-squares (RLS) algorithm called the ...

These aren't for the faint of heart.

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.18, moving -3.34% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.57%.